Importantly, RA patients with high MMP1/MMP3 expression exhibited a significant reduction in their disease activity, and inflammation at a short-term follow-up point and improved physical function when assessed after a prolonged period of DMARD therapy. The gene discussed is MMP3; the disease is rheumatoid arthritis.